(±) -Enitociclib

• Description:

  (±) -Enitociclib ((±) -BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E) . Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies[1][2].

• Product Name Alternative:

  (±) -BAY-1251152; (±) -VIP152

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; CDK; DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/racemic-enitociclib.html

• Purity:

  99.87

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  N=S(CC1=CC(NC2=NC=C(F)C(C3=CC=C(F)C=C3OC)=C2)=NC=C1)(C)=O

• Molecular Formula:

  C19H18F2N4O2S

• Molecular Weight:

  404.43

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Frigault MM, et al. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023 Nov 9;3 (11) :2268-2279.|[2]Tran S, et al. Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma[J]. Blood Neoplasia, 2025, 2 (1) : 100050.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK9

• CAS Number:

  [1610358-53-6]